`
`
`
`
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF WEST VIRGINIA
`AT CLARKSBURG
`
`
`v.
`
`
`
`
`
`
`
`
`C.A. No. 1:19-cv-00101 (IMK)
`
`
`MERCK SHARP & DOHME CORP.,
`
`
`Plaintiff,
`
`
`
`
`MYLAN PHARMACEUTICALS INC., and
`MYLAN INC.,
`
`
`
`
`
`
`Defendants.
`
`
`JOINT QUARTERLY STATUS REPORT
`
`Pursuant to this Court’s August 2, 2019 Order, the parties, by and through their
`
`undersigned counsel, jointly submit this Status Report.
`
`In re Sitagliptin MDL, 19-md-2902:
`
`On August 8, 2019, the Judicial Panel on Multidistrict Litigation issued a Transfer Order
`
`centralizing pretrial proceedings in this patent infringement litigation in the District of Delaware.
`
`Since transfer of the case to Delaware, the District of Delaware has entered a Scheduling Order
`
`on August 23, 2019 with the following key dates:
`
`Deadline / Event
`Date
`Feb. 14, 2020 Deadline to amend pleadings and join parties.
`Feb. 21, 2020 Deadline for substantial completion of document production.
`July 17, 2020 Deadline to file joint claim construction brief.
`Aug. 18, 2020 Claim construction hearing and status conference.
`Nov. 11, 2020 Close of fact discovery.
`July, 2 2021
`Close of expert discovery/expert depositions.
`July, 23 2021 Objections to expert testimony/Daubert motions due.
`TBD
`Deadline to file pretrial order.
`TBD
`Pre-trial conference.
`Dec. 13, 2021
`First day of three-day bench trial.
`
`
`1
`
`Merck Sharp & Dohme Corp. Exhibit 2019
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040
`Page 1
`
`
`
`Case 1:19-cv-00101-IMK Document 50 Filed 01/03/20 Page 2 of 3 PageID #: 696
`
`
`
`The parties have exchanged the required disclosures under the District of Delaware’s
`
`Default Standard for Discovery, Infringement Contentions, and Invalidity Contentions.
`
`Discovery remains ongoing.
`
`IPR2020-00040:
`
`On October 20, 2019, Mylan filed an Inter Partes Review Petition seeking cancellation
`
`of Claims 1–4, 17, 19, and 21–23 of U.S. Patent No. 7,326,708.
`
`
`
`
`
`Dated: January 3, 2020
`
`Respectfully submitted,
`
`SCHRADER COMPANION DUFF & LAW, PLLC
`
`/s/ James F. Companion
`James F. Companion (WV Bar #790)
`401 Main Street
`Wheeling, WV 26003
`(304) 233-3390
`jfc@schraderlaw.com
`
`Attorneys for Plaintiff
`Merck Sharp & Dohme Corp.
`
`OF COUNSEL:
`
`Bruce R. Genderson
`Jessamyn S. Berniker
`Stanley E. Fisher
`Alexander S. Zolan
`Shaun P. Mahaffy
`Anthony H. Sheh
`Jingyuan Luo
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5000
`F: (202) 434-5029
`bgenderson@wc.com
`jberniker@wc.com
`
`
`
`
`
`
`
`
`
`STEPTOE & JOHNSON, PLLC
`
`/s/ William J. O’Brien
`William J. O’Brien
`400 White Oaks Blvd.
`Bridgeport, WV 26330
`Phone: (304) 933-8000
`william.obrien@steptoe-johnson.com
`
`
`
`
`
`
`
`
`
`2
`
`Merck Sharp & Dohme Corp. Exhibit 2019
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040
`Page 2
`
`
`
`Case 1:19-cv-00101-IMK Document 50 Filed 01/03/20 Page 3 of 3 PageID #: 697
`
`
`
`sfisher@wc.com
`azolan@wc.com
`smahaffy@wc.com
`asheh@wc.com
`jluo@wc.com
`
`
`
`
`
`
`
`
`
`
`
`3
`
`Merck Sharp & Dohme Corp. Exhibit 2019
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040
`Page 3
`
`